Would extirpative pelvic surgery improve survival in gynecological metastases of lung cancer? Case report and review of the literature.


Journal

International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 17 04 2020
accepted: 11 08 2020
entrez: 25 1 2021
pubmed: 26 1 2021
medline: 26 1 2021
Statut: epublish

Résumé

Lung cancer is the 3rd most common cancer in the UK and the numbers of new cases increase every year. In contrast to gastrointestinal tumours and breast cancer, lung cancer, metastases to the female genital tract are incredibly rare with only five cases reported with uterine metastases on review of the published English literature. We report an interesting case of successful ongoing management of metastatic lung cancer to the pelvis along with an extensive literature review. A 47-year-old lady with recurrent respiratory tract symptoms and chest pain was diagnosed with advanced stage non-small-cell lung cancer (Stage T4N2M1A). Five years following diagnosis and several cycles of chemotherapy and radiotherapy, aged 52, she complained of post-menopausal bleeding and pelvic discomfort. An endometrial biopsy confirmed a malignancy morphologically and immunohistochemically similar to her lung adenocarcinoma, in keeping with metastatic disease. She underwent robotic surgery to excise the pelvic organs and successfully gain local disease control. The patient remains clinically stable 3 years following hysterectomy. Although metastases of lung cancer to uterus are very rare, any patient with abnormal uterine bleeding with known cancer should be investigated thoroughly to rule out metastatic disease. Combined multimodal treatment as in this case may increase overall survival.

Identifiants

pubmed: 33489697
doi: 10.1007/s13691-020-00441-3
pii: 441
pmc: PMC7797390
doi:

Types de publication

Case Reports

Langues

eng

Pagination

24-30

Informations de copyright

© The Japan Society of Clinical Oncology 2020.

Déclaration de conflit d'intérêts

Conflict of interestAll the authors confirm and declare that they have no conflict of interest.

Références

Int J Gynecol Cancer. 2007 May-Jun;17(3):731-4
pubmed: 17504386
Cancer. 1982 Nov 15;50(10):2163-9
pubmed: 7127256
Am J Case Rep. 2015 May 18;16:296-9
pubmed: 25981989
Cancer. 1984 May 1;53(9):1978-84
pubmed: 6322966
Am J Surg Pathol. 2005 Aug;29(8):997-1006
pubmed: 16006793
Mod Pathol. 1996 Nov;9(11):1066-70
pubmed: 8933517
Lung Cancer. 2014 Oct;86(1):78-84
pubmed: 25130083
Tumori. 2011 May-Jun;97(3):411-4
pubmed: 21789025
J Thorac Oncol. 2016 Oct;11(10):1653-71
pubmed: 27364315

Auteurs

Lusine Sevinyan (L)

Department of Gynae-Oncology, LEVEL B GOPD, Royal Surrey NHS Foundation Trust, Egerton Rd, Guildford, GU2 7XX UK.

Marianne Illsley (M)

Royal Surrey NHS Foundation Trust, Egerton Rd, Guildford, GU2 7XX UK.

Ben Haagsma (B)

Department of Histopathology, Royal Surrey NHS Foundation Trust, Guildford, UK.

Simon Butler-Manuel (S)

Department of Gynae-Oncology, LEVEL B GOPD, Royal Surrey NHS Foundation Trust, Egerton Rd, Guildford, GU2 7XX UK.

Patricia Ellis (P)

Department of Gynae-Oncology, LEVEL B GOPD, Royal Surrey NHS Foundation Trust, Egerton Rd, Guildford, GU2 7XX UK.

Thumuluru Kavitha Madhuri (TK)

School of Pharmacy & Biomolecular Sciences, University of Brighton, Brighton, UK.
Department of Gynae-Oncology, LEVEL B GOPD, Royal Surrey NHS Foundation Trust, Egerton Rd, Guildford, GU2 7XX UK.

Classifications MeSH